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           Viral infections trigger robust T cell responses, 
which are crucial to clear infection. However, 
in response to some viral infections, antiviral 
CD4 and CD8 T cells become unresponsive to 
viral antigens and are either physically deleted 
or persist in a nonfunctional (exhausted) state. 
This is characterized by the inability to pro-
duce antiviral and immune-stimulatory cyto-
kines, lyse virally infected cells, or proliferate 
(  1  –  3  ). Multiparameter loss of T cell function 
directly facilitates persistence, as indicated by 
the fact that prolonged T cell responses strongly 
correlate with clearance and control of hepati-
tis C virus (HCV) and HIV infections in hu-
mans and lymphocytic choriomeningitis virus 
(LCMV) infection in mice (  4  –  8  ). Thus, resto-
ration of T cell activity represents a potentially 
powerful approach to control established per-
sistent viral infections. Unfortunately, how-
ever, vaccines to restore antiviral T cell activity 
and control persistent viral infections have only 
been marginally successful (  9  ). The reasons 
underlying the failures are unclear because these 
same vaccines are often immunogenic when 
administered before infection. One explana-
tion is that although the vaccines are designed 
to stimulate T cells, they do not alleviate the 
immunosuppressive environment and, as a re-
sult, vaccine-activated T cells rapidly succumb 
to the same constraints that previously limited 
their responsiveness. By neutralizing the sup-
pressive factors and alleviating the immuno-
suppressive environment, antiviral T cells may 
become receptive to vaccine stimulation and 
enabled to fi  ght viral replication. 
  Recently, based on genetic deletion and 
antibody blockade studies, IL-10 was identifi  ed 
as a single, dominant factor that determines 
whether a virus infection is cleared acutely or 
persists (  5, 6  ). Antibody blockade of IL-10 dur-
ing an established persistent infection and after 
T cell exhaustion restored T cell function, 
leading to enhanced clearance of virus. During 
persistent viral infection, programmed death-1  –
  programmed death-ligand 1 (PD-1  –  PD-L1) 
interactions further limit T cell function, and 
antibody blockade of PD-L1 can stimulate 
T cell activity (  4  ). Thus, multiple immunosup-
pressive pathways are invoked during a persis-
tent viral infection that inhibit T cell immunity 
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twofold increase in the frequency and a greater than fi  ve-
fold increase in the number of IFN    -producing, virus-specifi  c 
CD8 T cells. A similar enhancement of CD8 T cell immu-
nity was observed by MHC class I tetramer staining (unpub-
lished data). Although IL-10R blockade alone increased the 
number of LCMV nucleoprotein (NP)   394-404  -specifi  c CD8 T 
cells compared with isotype treatment, DNA vaccine (which 
contained only LCMV-GP epitopes and not LCMV-NP epi-
topes) plus anti  –  IL-10R therapy did not enhance LCMV-
NP  396-404    –  specifi  c CD8 T cell responses ( Fig. 1 C ). Moreover, 
vaccination with the parental control DNA plasmid (i.e., that 
did not encode LCMV sequences) failed to further enhance 
T cell responses when combined with IL-10R blockade 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20071948/DC1). Thus, T cell stimulation resulted from 
the LCMV sequences encoded by the DNA vaccine and not 
a secondary response to heightened immune activation or 
nonspecifi  c activation by immunostimulatory sequences pre-
sent in the DNA vaccine. 
  IL-10R blockade followed by vaccination also signifi  -
cantly increased the number of functional virus-specifi  c CD8 
T cells (  Fig. 1 D  ). Whereas vaccination alone did not en-
hance virus-specifi  c CD8 T cell function, and IL-10R block-
ade alone only increased the number of TNF    -producing, 
virus-specifi  c T cells by approximately twofold, IL-10R block-
ade combined with vaccination stimulated a fourfold increase 
in the number of functional CD8 T cells that produced 
TNF     (  Fig. 1 D  ). Interestingly, the treatments did not sub-
stantially increase the frequency of TNF    -producing CD8 T 
cells as a proportion of virus-specifi  c cells (  Fig. 1 B  ). Rather, 
a dramatic increase in the absolute number of functional, 
cytokine-producing CD8 T cells was observed (  Fig. 1 D  ). 
  IL-10R blockade alone had a less dramatic eff  ect on CD4 
T cells than that observed for CD8 T cells, inducing a small 
but signifi  cant (P   <   0.05) 1.5  –  2-fold increase in the number 
of IFN    -producing CD4 T cells (  Fig. 2, B and C  ).   On the 
other hand, IL-10R blockade plus DNA vaccine therapy 
substantially increased the frequency and particularly the 
number (a sixfold increase compared with isotype treatment) 
of IFN    -producing CD4 T cells (  Fig. 2, B and C  ). Although, 
similar to virus-specifi  c CD8 T cell responses, IL-10R block-
ade alone or in combination with DNA vaccination only 
minimally enhanced the frequency of IL-2  –  producing CD4 
T cells and DNA vaccine or anti  –  IL-10R therapy alone only 
modestly aff  ected the number of IL-2 producing CD4 T 
cells; in contrast, cotreatment stimulated a robust fourfold in-
crease in the number of functional virus-specifi  c CD4 T cells 
(  Fig. 2, A and C  ). These data demonstrate that an otherwise 
ineff  ective vaccination strategy can stimulate robust T cell 
responses during persistent viral infection if IL-10  –  mediated 
immunosuppression is neutralized. 
  We next addressed whether the increased T cell function 
was caused by reactivation of previously exhausted T cells 
or from de novo priming of naive T cell precursors. To ad-
dress this issue, Thy1.1  +   TCR transgenic (tg) CD4 T cells 
(SMARTA cells; specifi  c to LCMV-GP  61-80   peptide) and 
and prevent virus clearance. The ability to restore T cell im-
munity through blockade of IL-10 or PD-L1 pathways ap-
pears distinct based on fi  ndings that PD-1 levels remained 
high in IL-10  –  defi  cient mice early after infection and that 
simultaneous blockade of IL-10 and PD-1 synergized to 
stimulate T cell activity during an established persistent viral 
infection (unpublished data). This is particularly important 
considering increased IL-10 expression is observed during 
many persistent viral infections in humans (e.g., HIV, HCV, 
and HBV) and is directly correlated with decreased T cell re-
sponsiveness and the failure to control viral replication (for 
review see [  10  ]). Thus, IL-10 might serve as a therapeutic 
target during many persistent viral infections to restore T cell 
responsiveness to vaccination and ultimately establish control 
of viral replication. 
    RESULTS AND DISCUSSION   
  To determine how the immunosuppressive environment 
aff  ects T cell responsiveness to vaccination during persistent 
viral infection, C57BL/6 mice were infected with LCMV 
Clone 13 (Cl 13). Infection with LCMV-Cl 13 rapidly in-
duces high-level expression of IL-10 that suppresses antiviral 
immunity and leads to viral persistence (  5, 6, 11  ). The pro-
found eff  ect IL-10 had on suppressing antiviral T cell activity 
and potentiating viral persistence, coupled with the contin-
ued high-levels of IL-10 expression throughout persistent 
infection (unpublished data) suggested that blocking IL-10  –
  mediated immunosuppression might now make T cells recep-
tive to exogenous stimulation (i.e., therapeutic vaccination). 
To determine whether IL-10 inhibits responsiveness to ther-
apeutic vaccination, LCMV-Cl 13 persistently infected mice 
were treated with isotype control antibody alone; treated 
with isotype control antibody and vaccinated with a DNA 
plasmid encoding the entire glycoprotein (GP) sequence of 
LCMV; treated with anti  –  IL-10R blocking antibody; or 
treated with a combination of anti  –  IL-10R blocking anti-
body plus DNA vaccination. Antibody treatment was initi-
ated on day 25 after Cl 13 infection and administered every 3 d 
for 5  –  6 treatments. DNA vaccination was administered on 
day 29 and 34 after virus infection (i.e., 4 and 9 d after the 
initiation of anti  –  IL-10R therapy). The treatment regimen is 
illustrated in   Fig. 1 A  .   
  Consistent with the inability of therapeutic vaccination 
to stimulate T cell responses during persistent infection (  12  ), 
DNA vaccination alone had no eff  ect on the frequency or 
number of virus-specifi  c CD8 T cells compared with un-
treated animals (  Fig. 1, B and C  ). On the other hand, IL-
10R blockade alone increased the frequency and number of 
IFN    -producing CD8 T cells against multiple LCMV epi-
topes (  Fig. 1, B and C  ), indicating that IL-10 actively sup-
presses T cell responses throughout persistent infection and 
that blocking IL-10R alone enhances T cell immunity. 
Importantly, IL-10R blockade combined with DNA vaccina-
tion dramatically enhanced T cell responses compared with 
either DNA vaccine or anti  –  IL-10R therapy alone (  Fig. 1 C  ). 
Anti  –  IL-10R plus DNA vaccine dual therapy induced a JEM VOL. 205, March 17, 2008  535 
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    Figure 1.         IL-10R blockade enables effective stimulation of antiviral T cell responses by therapeutic vaccination.   (A) Schematic representation 
of anti  –  IL-10R antibody treatment and DNA vaccination. LCMV-Cl 13  –  infected mice were treated with an isotype control antibody, treated with isotype 
control antibody and DNA vaccine (encoding the entire LCMV-GP), treated with an anti  –  IL-10R blocking antibody, or cotreated with DNA vaccine plus 
anti  –  IL-10R antibody. Anti  –  IL-10R treatment was initiated on day 25 after infection and continued every 3 d for 2 wk. DNA vaccination was administered 
on day 29 and 34 after infection. T cell responses were then analyzed on day 39 after infection. (B) Cytokine production was quantifi  ed by ex vivo peptide 
stimulation and intracellular staining. Flow plots are gated on CD8 T cells and illustrate the frequency of IFN    - and TNF   -producing,  LCMV-GP 33-41  –
 specifi  c CD8 T cells. Data are representative of four to fi  ve mice per group. (C) The graphs indicate the number of IFN   -producing  LCMV-GP 33-41 -, 
GP  276-286 -,  and  NP 396-404  -specific CD8 T cells after each treatment regimen. Circles represent individual mice. *, P   <   0.05 compared with untreated 
and DNA vaccination alone. **, P   <   0.05 compared with all other treatment groups. (D) The bar graph represents the mean fold increase in the number 
of TNF   -producing,  LCMV-GP 33-41  – specifi  c CD8 T cells in each treatment group compared with isotype treatment (which is set to 1). Values are the 
mean   ±   the SD of three experiments using four to six mice. *, P   <   0.05 compared with untreated and DNA vaccination alone; **, P   <   0.05 compared with 
all other treatment groups.     536 IL-10 BLOCKADE ENHANCES THERAPEUTIC VACCINATION | Brooks et al.
virus-specifi  c T cells (i.e., TNF    -producing tg CD8 T cells 
and IL-2  –  producing tg CD4 T cells; not depicted). Thus, 
IL-10R blockade permits the previously exhausted T cells to 
respond to vaccination. 
  To determine if IL-10R blockade and vaccination en-
hanced control of infection, virus titers were quantifi  ed af-
ter treatment and compared with pretreatment levels. After 
treatment, viral titers were similar in isotype and DNA vac-
cinated mice through 40 d after infection, whereas viral 
replication was signifi  cantly (P   <   0.05) decreased in anti  –
  IL-10R  –  treated mice, falling 17-fold after the resolution of 
therapy (  Fig. 4 A  ), indicating that the T cell responses elic-
ited by IL-10R blockade rapidly (i.e., within the 2-wk 
treatment regimen) impacted and decreased persistent viral 
replication. Importantly, anti  –  IL-10R plus DNA vaccine 
treatment resulted in an even greater enhanced ability to 
control and eliminate persistent viral replication, ultimately 
resulting in a 49-fold decrease in virus replication within 
the 2-wk timeframe between the initiation and completion 
of therapy (  Fig. 4 A  ).   Enhanced control of virus replication 
was also rapidly observed in the liver immediately after IL-
10R blockade alone, and virus titers were decreased even 
further in the liver after IL-10R blockade in combination 
with the DNA vaccine (  Fig. 4 B  ), demonstrating control of 
virus replication in nonlymphoid/eff  ector sites of infection. 
There was a discrepancy in the ability of some animals to 
Thy1.1  +   TCR tg CD8 T cells (P14 cells; specifi  c to LCMV 
GP  33-41   peptide) were cotransferred into Thy1.2  +   C57BL/6 
mice and the mice were subsequently infected with LCMV-
Cl 13. The cotransfer enabled analysis of LCMV-specifi  c 
CD4 and CD8 T cells present from the beginning of infec-
tion and which could be distinguished from endogenous 
(i.e., host-derived) antiviral T cells based on Thy1.1 versus 
Thy1.2 expression. Physiological numbers of these tg T cells 
were transferred to ensure that they respond similarly to their 
endogenous CD4 (  Fig. 2  ) and CD8 (  Fig. 1  ) T cell counter-
parts (  13  ). Similar to endogenous T cell responses (  Fig. 1 and 2  ), 
DNA vaccine alone did not increase the number of virus-
specifi  c tg CD8 or CD4 T cells, whereas IL-10R blockade 
stimulated a two- and fourfold increase in the number of tg 
CD8 and CD4 T cells, respectively (  Fig. 3  ).   IL-10R block-
ade in combination with DNA vaccination induced a dra-
matic sixfold increase in the number of tg virus-specifi  c CD8 
T cells compared with isotype control or DNA vaccine 
alone  –  treated mice and an approximately threefold increase 
when compared with IL-10R blockade alone (  Fig. 3 A  ). 
Similarly, IL-10R blockade in combination with vaccination 
stimulated an 11-fold increase in the number of virus-specifi  c 
tg CD4 T cells compared with isotype control or vaccine 
alone and a fourfold increase versus IL-10R blockade therapy 
alone (  Fig. 3 B  ). Like their endogenous counterparts, the 
combination therapy also elevated the number of functional 
    Figure 2.         CD4 T cell responses are enhanced by IL-10R blockade and vaccination.   (A) LCMV-Cl 13  –  infected mice were treated and analyzed as 
described in   Fig. 1  . The frequency of cytokine-producing, LCMV-GP  61-80  – specifi  c CD4 T cells was quantifi  ed by ex vivo peptide stimulation and intracellular 
staining. Flow plots are gated on CD4 T cells and illustrate the frequency of IFN    - and IL-2  –  producing, LCMV-GP  61-80  – specifi  c CD4 T cells after each treat-
ment (39 d after infection). Data are representative of 4  –  5 mice per group. (B) The graph illustrates the number of IFN   -producing,  LCMV-GP 61-80  – specifi  c 
CD4 T cells (quantifi  ed as described in   Fig. 1 C  ). *, P   <   0.05 compared with untreated and DNA vaccination alone. **, P   <   0.05 compared with all other 
treatment groups. (C) The bar graph illustrates the mean fold increase in the number of IL-2  –  producing, LCMV-GP  61-80  – specifi  c CD4 T cells after each 
treatment regimen compared with isotype treatment. Individual bars represent the mean value   ±   the SD of 3 experiments containing for 4  –  6 mice per 
group. *, P   <   0.05 compared with untreated and DNA vaccination alone. **, P   <   0.05 compared with all other treatment groups.   JEM VOL. 205, March 17, 2008  537 
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time virus had been cleared in both groups. However, it 
should be noted that the fold decrease in virus titers in the 
cotreated animals remained signifi  cantly lower than IL-
10R  –  treated animals alone well after the completion of 
therapy and only became equal after viral clearance (i.e., 
once there was no further decrease that could occur). Thus, 
although both treatments were highly eff  ective at control-
ling persistent viral replication, the ability to further increase 
T cell responses by vaccination enhanced control of persis-
tent viral infection. Viral replication remained absent after 
IL-10R blockade (  >  150 d after infection) and treated mice 
were protected from subsequent reinfection (not depicted). 
Interestingly, anti  –  IL-10R antibody treatment every 3 d 
boosted T cell responses, leading to control of persistent 
viral infection, whereas weekly treatments, including treat-
ment with twice the required dose of antibody, were in-
eff  ective (unpublished data), indicating that the timing of 
antibody therapy is an important determinant for therapeu-
tic effi   cacy. IL-10R blockade in combination with the con-
trol DNA vaccine (i.e., not encoding LCMV-GP) did not 
aff   ect virus titers compared with anti  –  IL-10R treatment 
alone, again demonstrating that the enhanced eff  ect of DNA 
vaccine was caused by stimulation of LCMV-specifi  c cells 
(not depicted). Thus, neutralizing IL-10  –  mediated immuno-
suppression facilitates the induction of robust virus-specifi  c 
eliminate virus infection after IL-10R blockade alone or in 
combination with DNA vaccination (  Fig. 4 A  ). Whereas 
some animals completely cleared virus infection after ther-
apy, other similarly treated animals still retained virus repli-
cation. It should be noted that   Fig. 4 (A and B)   illustrates 
the combined data from multiple experiments and that pre-
therapy virus titers varied between experiments. However, 
in general, animals with higher pretreatment virus titers 
corresponded to higher levels of virus replication after treat-
ment, and results were signifi  cant within experiments. The 
diff  erence in virus clearance kinetics after treatment was not 
caused by the gender or the age of the mice (unpublished 
data). Importantly, when the fold decrease in virus titers 
were quantifi  ed, the enhanced antiviral eff  ect of IL-10R 
blockade plus DNA vaccination became even more evident 
(  Fig. 4 C  ), illustrating that the control of persistent virus 
replication was maintained well after the cessation of ther-
apy and until virus infection was cleared. IL-10R treatment 
alone was highly eff  ective to control persistent viral infec-
tion; however, IL-10R therapy plus DNA vaccination en-
hanced control of virus replication even further (  Fig. 4 D  ). 
By day 65 after infection (28 d after the completion of ther-
apy), the fold decrease in virus titers was similar in mice that 
received IL-10R treatment alone and those that received 
IL-10R plus DNA vaccine (  Fig. 4, C and D  ) because by this 
    Figure 3.         IL-10R blockade combined with vaccination restores T cell function.   Before infection, mice were seeded with LCMV-specifi  c, Thy1.1  + , 
TCR tg CD8  +   (P14; A), and CD4  +   (SMARTA; B) T cells and infected with LCMV-Cl 13. Mice were treated with isotype control antibody, anti  –  IL-10R blocking 
antibody, and/or DNA vaccine, as described in   Fig. 1 A  . Bar graphs indicate the fold increase in the number of P14 and SMARTA cells on day 39 after infec-
tion. Individual bars represent the mean   ±   the SD of fi  ve mice per group. *, signifi  cant (P   <   0.05) increase in the mean number versus isotype and DNA 
vaccine alone. **, signifi  cant (P   <   0.05) increase versus all other conditions.     538 IL-10 BLOCKADE ENHANCES THERAPEUTIC VACCINATION | Brooks et al.
viral infection allows an otherwise ineff  ective DNA vaccine to 
potently stimulate antiviral CD4 and CD8 T cell responses 
and control viral replication. Using tg cells, we showed that 
IL-10R blockade in combination with vaccination improved 
and expanded eff  ector activity in previously exhausted T cells 
even after prolonged exposure to an immuno  suppressive mi-
lieu. An independent fi  nding (see Ha et al. [  14  ] on p.   5    4    3   
of this issue) demonstrated that blockade of a diff  erent host 
immunosuppressive molecule (PD-L1) was similarly able to 
restore effi   cacy of therapeutic vaccination and stimulate antiviral 
T cell responses during persistent viral infection. Together, these 
fi  ndings establish the concept that the immunosuppressive 
environment inhibits therapeutic vaccination, and indicates a 
T cell responses with an enhanced ability to control persis-
tent viral infection. 
  In this study, we establish the concept that the immuno-
suppressive environment inhibits the ability of vaccines to re-
store T cell immunity during an established persistent viral 
infection. Our results shed light on the enigma of why thera-
peutic administration of a vaccine agent is unsuccessful, 
whereas administration of the same vaccine to pathogen-naive 
individuals (in which no immunosuppressive environment 
exists) is highly eff  ective. Once the immunosuppressive signals 
that limit T cell function are neutralized, T cells become re-
ceptive to stimulation by vaccines. Specifi  cally, we demonstrate 
that antibody neutralization of IL-10 activity during persistent 
    Figure 4.         Accelerated control of persistent viral infection by alleviating the immunosuppressive environment and vaccinating to stimulate 
T cell responses.   (A) LCMV-Cl 13  –  infected mice were infected and treated as described in   Fig. 1 A  . Serum viral titers were quantifi  ed on day 25 (gray circles, 
before treatment) and day 40 (white circles, after the completion of all therapeutic treatments) after infection. Each circle represents the virus titers in a 
single mouse on day 25 and 40 after infection. The dashed line indicates the level of detection of the plaque assay (200 PFU/ml). *, indicates a signifi  cant 
(P   <   0.05) decrease in virus titers on day 40 after infection compared with untreated or to DNA vaccination alone. **, indicates a signifi  cant (P   <   0.05) 
decrease in virus titers on day 40 after infection compared with isotype antibody treatment, DNA vaccine alone, or IL-10R antibody treatment alone. The 
numbers above each group indicate the mean fold decrease in virus titers between day 25 and 40 after infection. The graph contains data from three 
separate experiments. (B) The graph illustrates the virus titer in the liver of individual mice 3 d after the withdrawal of therapy. Each circle represents the 
liver virus titers in an individual mouse on day 40 after infection. The dashed line indicates the level of detection of the plaque assay (200 PFU/ml). *, indi-
cates a signifi  cant (P   <   0.05) decrease in virus titers on day 40 after infection compared with untreated mice or with DNA vaccination alone. **, indicates 
a signifi  cant (P   <   0.05) decrease in virus titers on day 40 after infection compared with isotype antibody treatment, DNA vaccine alone, or IL-10R anti-
body treatment alone. (C) The graph illustrates a longitudinal analysis of the mean fold decrease in serum virus titers after isotype antibody treatment 
(white circles), IL-10R antibody blockade (gray circles), or IL-10R antibody blockade plus DNA vaccination (black circles). The mean fold decrease in each 
group was determined by dividing the pretreatment virus titers in each mouse (on day 25 after infection) by the virus titer in the same mouse on the 
indicated day after infection. Each circle represents the mean fold decrease   ±   the SD in viral titers of four to fi  ve mice per group. The gray box indicates 
the duration of antibody treatment. (D) Longitudinal analysis of serum viral titers were performed after LCMV-Cl 13 infection after isotype antibody treat-
ment (white circles), IL-10R antibody blockade (gray circles), or IL-10R antibody blockade plus DNA vaccination (black circles). To better standardize virus 
titers, all groups were initially normalized to the virus titer of the isotype-treated group on day 25 after infection (i.e., before treatment). Each circle rep-
resents the mean virus titer of 4  –  5 mice on the indicated day after infection. The gray box indicates the duration of antibody treatment. The dashed line 
indicates the level of detection of the plaque assay (200 PFU/ml).     JEM VOL. 205, March 17, 2008  539 
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vaccines and stimulate T cells. We are currently exploring 
these scenarios. Ultimately, the determination of the cell 
types that present DNA-derived antigens and how IL-10 
dysregulates antigen presentation should yield insights into 
the cellular interactions that potentiate viral persistence and 
aid in the development of immunotherapies to correct anti-
gen presentation and enhance immunity. 
  In our system, IL-10R blockade in combination with 
DNA vaccine stimulated a more rapid viral clearance than 
IL-10R blockade alone, although IL-10R blockade alone 
does eff  ectively control persistent viral replication. These data 
are important because it illustrates that solely blocking IL-10  –
  mediated immunosuppression elicits T cell responses capa-
ble of controlling persistent LCMV infection. However, 
clearance of LCMV is particularly dependent on and suscep-
tible to the levels of T cell activity. In other infections, such 
as HIV and HCV, in which T cells are important for virus 
control but not necessarily as eff  ective as against LCMV, the 
ability to further elevate T cell responses through vaccination 
is particularly desirable. Moreover, LCMV-Cl 13 infection is 
naturally cleared within 60  –  150 d (  26  ). Thus, although, IL-
10R blockade alone increases T cell responses to a suffi   cient 
level to accelerate LCMV clearance, stronger T cell responses 
will likely be required to control other persistent viral infec-
tions that are not naturally resolved. Although the increase in 
virus-specifi  c T cells after IL-10R blockade alone eliminates 
persistent LCMV infection, when larger T cell responses are 
required to control other virus infections, then our data es-
tablish that blocking IL-10R and stimulating with a vaccine 
will be highly eff  ective. For example, IL-10R blockade in 
combination with DNA vaccine stimulated a 5  –  10 fold in-
crease in the total number of virus-specifi  c T cells (which is 
greater than IL-10R blockade alone;   Figs. 2 and 3  ) and, im-
portantly, increased the population of T cells able to simulta-
neously produce multiple cytokines in response to viral 
antigen. It is these polyfunctional T cells that are associated 
with enhanced control of HIV infection (  27  ). In fact, the 
further enhancement of T cell responses may be the thing 
that ultimately tips the balance to immune control and clear-
ance of persistent viral replication in humans. In essence, our 
study illustrates that in situations in which maximal T cell 
responses are required to control virus replication, neutralization 
of the immunosuppressive environment is essential to allow 
T cell  –  stimulating agents to elicit their greatest response. 
  The failure of vaccines to trigger T cell immunity when 
administered during an established persistent viral infection 
has largely been enigmatic because these same vaccines are 
often immunogenic and can stimulate T cell responses when 
given prophylactically. Our data now clarifi  es this discrep-
ancy. Although a vaccine may inherently stimulate T cell ac-
tivity, when it is administered in the context of a persistent 
viral infection, the immunosuppressive constraints continue 
to inhibit T cell responsiveness. Consistent with our fi  ndings, 
when a vaccine is administered to HIV-infected patients in 
which virus replication is suppressed by antiretroviral ther-
apy, T cells are receptive to stimulation (for review see [  28  ]). 
potentially powerful approach to enhance T cell immunity 
and combat persistent viral infections. 
  Multiple lines of evidence indicate that IL-10 mediates 
suppression during chronic infections in humans. Elevated 
IL-10 levels are observed during HIV, HCV, and HBV in-
fections and, similar to LCMV infection, the extent of IL-10 
expression correlates with diminished T cell activity and in-
creased virus replication (  10  ). Further, in vitro blockade of 
IL-10 in peripheral blood mononuclear cells from HIV and 
HCV chronically infected human  ’  s restored T cell activity 
(  15  –  18  ). Recent studies also indicate that genetic polymor-
phisms in the IL-10 promoter that reduce IL-10 production 
are associated with clearance of HCV infection and enhanced 
virus control during chronic HCV, HBV, HIV, and EBV in-
fections (  19  –  22  ). Thus, IL-10 neutralization in persistently 
infected humans might enable vaccines to restore antiviral T 
cell immunity and control persistent infections. 
  It is interesting that IL-10R blockade alone or in combi-
nation with vaccination increased the number of functional, 
cytokine-producing T cells, but at the population level did 
not substantially increase the overall frequency of cytokine-
producing, virus-specifi  c T cells. Nevertheless, the increased 
number of functional cells was able to control infection. 
These fi  ndings have important implications for the treatment 
of persistent infections because they suggest that complete 
functional restoration at the cellular level may not be required 
to control viral replication. Rather, it might be suffi   cient to 
therapeutically elevate the absolute number of functional 
virus-specifi  c T cells to control viral persistence. Thus, in hu-
man clinical trials testing candidate vaccines, increases in the 
absolute number of antiviral T cells should be carefully con-
sidered as a therapeutic endpoint. 
  Given that high levels of viral antigen exist during persis-
tence, it is surprising that the addition of more antigen 
through vaccination can actually further elevate antiviral T 
cell numbers. Our results with IL-10R blockade suggest that 
the failure of T cell activity is not necessarily caused by the 
high levels of viral antigen per se, but rather to the milieu in 
which viral antigens are being processed and/or presented to 
T cells. The increased T cell activity observed after vaccina-
tion may be a function of multiple factors. First, viral antigen 
during persistent infection may not be presented in a manner 
that robustly stimulates T cell responses. Because DCs are a 
primary target of LCMV-Cl 13 (  23  ), the majority of DCs 
presenting viral antigens may still exhibit some level of dys-
function even after IL-10R blockade. DCs can present DNA-
derived antigens after vaccination (  24, 25  ). Consequently, 
newly recruited DCs (which have not been rendered dys-
functional by LCMV) may be better equipped to stimulate 
T cell activity. Second, because DNA vaccines bypass the re-
quirement for antigen-specifi  c recognition, non-LCMV  –
  specific B cells may also become a source of antigen 
presentation and further amplify T cell activity. Third, addi-
tional APC populations (i.e., macrophages, B cells, and dif-
ferent DC subsets) that would otherwise not present to T 
cells during infection may acquire antigen derived from DNA 540 IL-10 BLOCKADE ENHANCES THERAPEUTIC VACCINATION | Brooks et al.
CD4 (clone RM4-5; BD Biosciences) and CD8 (clone 53  –  6.7; Caltag). 
Cells were fi   xed, permeabilized, and stained with antibodies to TNF-     
(clone MP6-XT22), IFN-     (clone XMG1.2), and IL-2 (clone JES6-5H4). 
Flow cytometric analysis was performed using the Digital LSR II (Becton 
Dickinson). The absolute number of virus-specifi  c T cells was determined 
by multiplying the frequency of cytokine  +   cells by the total number of cells 
in the spleen. 
  In vivo IL-10R  –  specifi  c antibody treatment.     C57BL/6 mice received 
250   μ  g/mouse/injection i.p. of IL-10R  –  specifi  c antibody (clone 1B1.3a; pro-
vided by Schering-Plough) or rat IgG  1   isotype control antibody (clone KM1.
GL113 [anti  –    Escherichia coli       -galactosidase]; provided by Schering-Plough) 
beginning 25 d after infection and continuing every 3 d for 5  –  6 treatments. 
  DNA vaccinations.     Plasmid pCMV-GP encodes the entire LCMV glyco-
protein. The parental control vector pCMV is the same, except that it con-
tains no LCMV sequences. The plasmids were provided by Lindsay Whitton 
(The Scripps Research Institute, La Jolla, CA), and the construction of these 
plasmids has been previously described (  31  ). pCMV-GP encodes both CD4 
and CD8 T cell LCMV GP epitopes, but not CD4 and CD8 T cell LCMV 
NP epitopes. Plasmids were propagated in parallel in   E. coli   and purifi  ed us-
ing an endotoxin-free plasmid purifi  cation kit (QIAGEN). C57BL/6 mice 
received DNA injections (bilateral 50   μ  l injections of plasmid DNA in saline 
(100   μ  g plasmid/mouse) into the anterior tibial muscles) on days 29 and 34 
after LCMV-Cl 13 infection. 
  Statistical analysis.     Student  ’  s   t   tests and Mann-Whitney Rank Sum tests 
were performed using SigmaStat 2.0 software (Systat Software, Inc.). 
  Online supplemental material.     Fig. S1 shows that the LCMV sequences 
in the DNA vaccine are responsible for stimulating antiviral T cell responses. 
The online version of this article is available at http://www.jem.org/cgi/
content/full/jem.20071948/DC1. 
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